Comparative Pharmacology
Head-to-head clinical analysis: UREX versus UROBAK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UREX versus UROBAK.
UREX vs UROBAK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Urex (methenamine hippurate) is hydrolyzed in acidic urine to formaldehyde and ammonia. Formaldehyde denatures bacterial proteins and nucleic acids, exerting a nonspecific bactericidal effect. The hippuric acid component maintains urinary acidity.
UROBAK (methenamine hippurate) is a prodrug that hydrolyzes to formaldehyde in acidic urine (pH ≤ 5.5). Formaldehyde denatures bacterial proteins and nucleic acids, exerting a broad-spectrum bacteriostatic effect. The hippurate component may enhance urinary acidification.
100 mg orally twice daily for 3 days (uncomplicated UTI) or 100 mg orally once daily for 5 days (prophylaxis).
500 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is 14-18 hours in patients with normal renal function. In renal impairment, half-life is significantly prolonged (up to 40 hours in severe impairment), necessitating dose adjustment.
6-8 hours (prolonged in renal impairment).
Primarily renal: approximately 60-80% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion. Biliary/fecal elimination accounts for <5%.
Primarily renal (85% unchanged); 15% biliary/fecal.
Category C
Category C
Urinary Anti-infective
Urinary Anti-infective